THE NOVEL TYPE II CD20 ANTIBODY GA101 MEDIATES SUPERIOR B CELL DEPLETION IN WHOLE BLOOD FROM HEALTHY VOLUNTEERS AND B-CLL PATIENTS

被引：0
|
作者：
Herter, S. [1 ]
Del Giudice, I. [2 ]
Schmidt, C. [1 ]
Fauti, T. [1 ]
Klein, C. [3 ]
Umana, P. [1 ]
Dyer, M. J. S. [4 ]
Foa, R. [2 ]
Grau, R. [1 ]
机构：
[1] Glycart Biotechnol AG, Schlieren, Switzerland
[2] Univ Roma La Sapienza, Rome, Italy
[3] Roche Diagnost GmbH, Penzberg, Germany
[4] Univ Leicester, Leicester, Leics, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0910
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [31] γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
    Braza, Mounia Sabrina
    Klein, Bernard
    Fiol, Genevieve
    Rossi, Jean-Francois
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (03): : 400 - 407
  • [32] LFB-R603 A THERAPEUTIC CD20 ANTIBODY MEDIATES A SUPERIOR ANTITUMORAL EFFICACY IN NON-HODGKING LYMPHOMA XENOGRAFT MODEL AND B-CELL DEPLETION IN CYNOMOLGUS MONKEYS
    Dumontet, C.
    Herveau, S.
    Tournebize, C.
    Meterreau, J. L.
    Esteves, I.
    Fournes, B.
    Dhainaut, F.
    Bodenant, B.
    Picot, B.
    Azam, P.
    Khandoudi, N.
    Salcedo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 179 - 179
  • [33] Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial.
    Goede, Valentin
    Fischer, Kirsten
    Raymonde, Busch
    Ulrich, Jaeger
    Dilhuydy, Marie-Sarah
    Wickham, Nicholas
    De Guibert, Sophie
    Fink, Anna Maria
    Hagist, Susanne
    Pflug, Natali
    Bahlo, Jasmin
    Kranz, Gabriele
    Bieska, Gabriel
    Humphrey, Kathryn
    Bishop, Helen
    Wenger, Michael
    Hallek, Michael
    BLOOD, 2010, 116 (21) : 597 - 597
  • [34] Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way
    Niederfellner, Gerhard J.
    Lammens, Alfred
    Schwaiger, Manfred
    Georges, Guy
    Wiechmann, Kornelius
    Franke, Andreas
    Schaefer, Wolfgang
    Jenewein, Stefan
    Slootstra, Jerry
    Moessner, Ekkehard
    Umana, Pablo
    Hopfner, Karl-Peter
    Klein, Christian
    BLOOD, 2009, 114 (22) : 1435 - 1435
  • [35] Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients:: impact on clonal B-cell apoptosis
    Kay, NE
    Han, L
    Bone, N
    Williams, G
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) : 760 - 767
  • [36] AN IN VITRO TEST PREDICTIVE OF THE IN VIVO B CELL RITUXIMAB-TRIGGERED DEPLETION, UNDERLINES THE POTENTIAL THERAPEUTIC INTEREST OF A RECOMBINANT ANTI-CD20 IGA IN B-CLL PATIENTS
    Congy, N.
    Ysebaert, L.
    Apoil, P.
    Tiraby, G.
    Drocourt, D.
    Abbal, M.
    Blancher, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 515 - 515
  • [37] Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
    Tobinai, K.
    Ogura, M.
    Hatake, K.
    Kobayashi, Y.
    Mori, M.
    Uchida, T.
    Suzuki, T.
    Terui, Y.
    Yokoyama, M.
    Hotta, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
    Moessner, Ekkehard
    Bruenker, Peter
    Moser, Samuel
    Puentener, Ursula
    Schmidt, Carla
    Herter, Sylvia
    Grau, Roger
    Gerdes, Christian
    Nopora, Adam
    van Puijenbroek, Erwin
    Ferrara, Claudia
    Sondermann, Peter
    Jaeger, Christiane
    Strein, Pamela
    Fertig, Georg
    Friess, Thomas
    Schuell, Christine
    Bauer, Sabine
    Dal Porto, Joseph
    Del Nagro, Christopher
    Dabbagh, Karim
    Dyer, Martin J. S.
    Poppema, Sibrand
    Klein, Christian
    Umana, Pablo
    BLOOD, 2010, 115 (22) : 4393 - 4402
  • [39] Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
    Sehn, Laurie H.
    Goy, Andre
    Offner, Fritz C.
    Martinelli, Giovanni
    Caballero, M. Dolores
    Gadeberg, Ole
    Baetz, Tara
    Zelenetz, Andrew D.
    Gaidano, Gianluca
    Fayad, Luis E.
    Buckstein, Rena
    Friedberg, Jonathan W.
    Crump, Michael
    Jaksic, Branimir
    Zinzani, Pier Luigi
    Iyer, Swaminathan Padmanabhan
    Sahin, Deniz
    Chai, Akiko
    Fingerle-Rowson, Guenter
    Press, Oliver W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3467 - +
  • [40] New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma
    Alduau, Waleed
    Potluri, Sandeep
    Ivanov, Andrei
    Honeychurch, Jamie
    Beers, Stephen A.
    Chan, Claude
    Shimada, Kazayuki
    Glennie, Martin J.
    Cragg, Mark S.
    Illidge, Tim
    BLOOD, 2009, 114 (22) : 302 - 303
12345